Our Science
To create a medicine
to treat diseases

of the nervous system
Our Mission
To improve people’s quality
of life
through innovative,
sustainable and effective pain relief

Therapeutic focus » Our Science

PN6047 – a unique mode of action

PharmNovo’s mission is to discover new, safe, and effective drugs to help patients suffering from neuropathic pain. We combine innovative chemistry and bioscience to discover new treatments for neuropathic pain and other diseases of the nervous system.

Our drug candidate PN6047 is an agonist, a  drug that binds to and activates a specific receptor. It is a potent, carefully developed, small molecule that selectively activates the delta (δ) opioid receptor (DOR).

PN6047 does not, like conventional opioids, affect the mu (μ) opioid receptor, which is known to provide adequate relief for acute pain, but also causes addiction and severe side effects, such as  respiratory depression, abuse potential, itching and constipation.

Activating the delta receptor does not provide acute pain relief - but it produces an excellent reversal of neuropathic pain in animal models.

The approach of  activating the delta receptor is entirely new. The underlying concept is to specifically activate the beneficial parts of the system while avoiding the type of activation that results in unwanted side effects.

Latest news

View all
October 3, 2023

Phase I study completed for PN6047

In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.

Read more
October 3, 2023

PharmNovo presented at the BioStock Investor Meeting

PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.

Read more
September 28, 2023

No abuse potential shown in preclinical studies

We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.

Read more
September 10, 2023

Latest progress from PharmNovo at EFIC

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

Read more